Ocular Therapeutix (OCUL) Stock Price, News & Analysis

Company Overview

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based technology to design sustained-release treatments intended to deliver medication to ocular tissues over extended periods and potentially reduce the need for frequent eye drops or injections.

Its commercial product, Dextenza, is a resorbable intracanalicular insert that delivers dexamethasone to the ocular surface for the treatment of inflammation and pain following ophthalmic surgery. Dextenza is inserted into the tear duct by an eye-care professional and is designed to provide medication for up to 30 days. The company’s development pipeline includes AXPAXLI, an extended-release intravitreal implant containing axitinib that is being studied for retinal diseases, including wet age-related macular degeneration.

Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts. The company’s products and clinical programs are primarily directed at the U.S. ophthalmology market, while its research and development activities support potential international expansion. Ocular Therapeutix is led by President and Chief Executive Officer Pravin U. Dugel, an ophthalmologist and industry executive with experience in retinal disease and ophthalmic drug development.

Key Stats

• Today's Range: $10.37 to $10.94
• 50-Day Range: $8.17 to $11.73
• 52-Week Range: $6.23 to $16.44
• Volume: 2.63 million shs
• Average Volume: 2.59 million shs
• Market Capitalization: $2.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.75
• Consensus Rating: Moderate Buy

Ocular Therapeutix Stock Analysis - MarketRank™

Ocular Therapeutix scored higher than 74% of companies evaluated by MarketBeat, and ranked 193rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ocular Therapeutix has a consensus price target of $25.75, representing about 145.5% upside from its current price of $10.49.

Amount of Analyst Coverage

Ocular Therapeutix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.47) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocular Therapeutix is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocular Therapeutix is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ocular Therapeutix has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.18% of the float of Ocular Therapeutix has been sold short.

Short Interest Ratio / Days to Cover

Ocular Therapeutix has a short interest ratio ("days to cover") of 8.96.

Change versus previous month

Short interest in Ocular Therapeutix has recently decreased by 1.61%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocular Therapeutix does not currently pay a dividend.

Dividend Growth

Ocular Therapeutix does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.55

News Sentiment

Ocular Therapeutix has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Ocular Therapeutix this week, compared to 6 articles on an average week.

Search Interest

13 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

3 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $321,827.00 in company stock.

Percentage Held by Insiders

3.10% of the stock of Ocular Therapeutix is held by insiders.

Percentage Held by Institutions

59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/13/2026
• 2026 Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OCUL
• CIK: 1393434
• Web: www.ocutx.com
• Phone: (781) 357-4000
• Fax: 781-357-4001
• Employees: 325
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Ocular Therapeutix: $25.75
• High Price Target: $31.00
• Low Price Target: $18.00
• Potential Upside/Downside: +145.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$265.94 million
• Net Margins: -579.10%
• Pretax Margin: -579.10%
• Return on Equity: -59.89%
• Return on Assets: -45.99%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 13.10
• Quick Ratio: 13.03

Sales & Book Value

• Annual Sales: $51.95 million
• Price / Sales: 44.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 3.42

Miscellaneous

• Outstanding Shares: 219,620,000
• Free Float: 212,808,000
• Market Cap: $2.30 billion
• Optionable: Optionable
• Beta: 0.97